Lacey Laurence Francis, Armstrong David J, Royle Emily, Magee Pamela, Pourshahidi L Kirsty, Ray Sumantra, Strain J J, McSorley Emeir
Lacey Solutions Limited, Skerries, County Dublin, Ireland.
Nutrition Innovation Centre for Food and Health (NICHE), Ulster University, Coleraine, UK.
BMJ Nutr Prev Health. 2022 May 26;5(1):98-105. doi: 10.1136/bmjnph-2021-000382. eCollection 2022.
This study investigated the cost-effectiveness of vitamin D supplementation in older adults in Ireland, with year-round vitamin D deficiency (serum 25-hydroxyvitamin D concentration <30 nmol/L) (13% of Irish adults), from the perspective of the Health Service Executive.
Three age groups were investigated: (1) ≥50 years, (2) ≥60 years and (3) ≥70 years. Based on the clinical literature, vitamin D supplementation may: (1) decrease all-cause mortality by 7% and (2) reduce hip fractures by 16% and non-hip fractures by 20%. A discount rate of 4% was applied to life years and quality-adjusted life years (QALYs) gained, and healthcare costs. The annual healthcare costs per patient used in the model are based on the average annual health resource use over the 5-year time horizon of the model.
The cost/QALY estimates in all three age groups are below the usually acceptable cost-effectiveness threshold of €20 000/QALY. The most cost-effective and least costly intervention was in adults ≥70 years. For this age group, the average annual costs and outcomes would be approximately €5.6 million, 1044 QALYs gained, with a cost/QALY of approximately €5400. The results are most sensitive to the mortality risk reduction following vitamin D supplementation.
The cost-effectiveness of vitamin D supplementation is most robust in adults ≥70 years. Clinical uncertainty in the magnitude of the benefits of vitamin D supplementation could be further addressed by means of: (1) performing a clinical research study or (2) conducting a pilot/regional study, prior to reaching a decision to invest in a nationwide programme.
本研究从爱尔兰卫生服务局的角度,调查了爱尔兰全年维生素D缺乏(血清25-羟基维生素D浓度<30 nmol/L)的老年人(占爱尔兰成年人的13%)补充维生素D的成本效益。
调查了三个年龄组:(1)≥50岁,(2)≥60岁,(3)≥70岁。根据临床文献,补充维生素D可能:(1)使全因死亡率降低7%,(2)使髋部骨折减少16%,非髋部骨折减少20%。对获得的生命年和质量调整生命年(QALY)以及医疗保健成本应用4%的贴现率。模型中使用的每位患者的年度医疗保健成本基于模型5年时间范围内的平均年度卫生资源使用情况。
所有三个年龄组的成本/QALY估计值均低于通常可接受的20000欧元/QALY的成本效益阈值。最具成本效益且成本最低的干预措施针对≥70岁的成年人。对于该年龄组,平均年度成本和结果约为560万欧元,获得1044个QALY,成本/QALY约为5400欧元。结果对补充维生素D后降低的死亡风险最为敏感。
补充维生素D的成本效益在≥70岁的成年人中最为显著。在决定投资全国性项目之前,可通过以下方式进一步解决补充维生素D益处大小方面的临床不确定性:(1)进行临床研究或(2)开展试点/区域研究。